Bevacizumab (commonly referred to as AvastinTM), Genentech Inc, San Francisco, CA, USA reportedly has potential off-label use for treating conditions related to Vascular Endothelial Growth Factor (VEGF) excesses, eg, Age-related macular degeneration, retinal vascular occlusions, diabetic macular edema, etc. Ahmed and colleagues1 report their experience with intravitreal Bevacizumab for ROP. The gene discussed is VEGFA; the disease is retinopathy of prematurity.